2022 American Transplant Congress » Kidney Immunosuppression: Induction Therapy

7:00pm-8:00pm

A Single Center Experience of Simultaneous Heart-Kidney Transplantation

A. Samra¹, A. Mattoo²

7:00pm-8:00pm

Analysis of Induction Dose and Incidence of CMV Viremia in High Risk (HR; D+/R-) Renal Transplant Recipients

K. Shimko, M. Pittappilly, R. Chowdhury, H. Karimi, C. Puttarajappa, M. Wijkstrom, R. Mehta

7:00pm-8:00pm

Effect of Anti Thymocyte Globulin Induction Therapy in Kidney Transplantation Network Meta-Analysis Using Recent Data

S. Hwang, J. Song, K. Kim, S. Lee

7:00pm-8:00pm

Efficacy and Safety of a Delayed Graft Function Protocol in Kidney Transplant Recipients

V. Vu¹, S. Bhayana², H. Sweiss¹, N. Castro¹, R. Hall¹, J. Nelson¹

7:00pm-8:00pm

Extended Duration of Rabbit Antithymocyte Globulin (rATG) Induction in Kidney and Kidney/Pancreas Transplant Recipients

D. Majmundar, A. Di Carlo, A. Diamond

7:00pm-8:00pm

First-in-human Study Of Lis1, A Novel Glyco-humanized Anti-lymphocyte Swine Polyclonal Antibody, In Kidney Transplantation: Safety And Efficacy

J. Slatinska¹, B. Vanhove², M. Kolarova¹, F. Shneiker², J. Rousse², C. Galli³, J. Bach⁴, E. Cozzi⁵, J. Soulillou⁶, O. Duvaux², O. Viklicky¹

7:00pm-8:00pm

Fixed-Dose Rituximab for Pre-Transplant DSA in Kidney Transplant Recipients

K. Progar¹, K. Kurwicki², N. Nesselhauf³, J. Hagopian⁴, S. January⁵, H. Wijeweera⁶, M. McCloskey⁷, M. Merzkani⁸, R. Delos Santos⁹

7:00pm-8:00pm

Impact of ATG Dose Reduction on Kidney Transplant Outcomes During the Covid-19 Pandemic

P. A. Than¹, F. De Leon¹, K. Jen², N. Goussous¹, R. V. Perez¹, A. X. Wang³

7:00pm-8:00pm

Impact of Immunosuppressive Medications on SARS-CoV-2 Vaccination Response in Kidney Transplant Patients

O. Sogbein¹, A. Rizvi², M. Mujtaba³, M. Kueht⁴, J. Fair⁴, A. Gamilla-Crudo³, S. Hussain⁵

7:00pm-8:00pm

Long-Term Low-Dose Corticosteroid Therapy Can Suppress Calcineurin Inhibitor Induced Nephrotoxicity without Steroid-Related Complication in Living Kidney Transplant Recipient

H. Sasaki, H. Harada, D. Takamoto, Y. Takada, S. Harada, H. Tanaka

7:00pm-8:00pm

Optimal Dose of Anti-Thymocyte Globulin to Improve Allograft and Patient Survival After Kidney Transplantation: Analysis from Korean Organ Transplantation Registry Data

Y. Shim, H. Kwon, Y. Kim, H. Kwon, J. Jung, Y. Ko, S. Lim, S. Shin

7:00pm-8:00pm

Outcomes of Primary Kidney Transplant Recipients with Human Immunodeficiency Virus According to Induction Immunosuppression in the United States

K. Bhunia¹, K. Swanson¹, A. Bregman¹, R. El-Rifai¹, R. Spong¹, S. Jackson², S. Riad³

7:00pm-8:00pm

Post-Kidney Transplant Dementia Risk by Modifiable Risk Factors and CNIs Among Older Recipients

Y. Chen¹, J. Ahn¹, N. Chu¹, S. Bae¹, M. A. Schnitzler², G. Hess³, K. Lentine⁴, D. Segev⁵, M. McAdams-DeMarco¹

7:00pm-8:00pm

Reduction of Rabbit Anti-Thymocyte Globulin Dosing for Induction of Kidney Transplant During the COVID-19 Pandemic

C. Burrelli¹, S. Gundling¹, D. Ecabert¹, R. Powell¹, A. Padiyar¹, K. Andreoni¹, K. Chavin², A. Bixby¹

7:00pm-8:00pm

Single Dose Alemtuzemab Provides Comparable Rejection Free and Infection Free Survival Compared to Double Dose Alemtuzumab. In Comparison to Alemtuzemab, Basiliximab Has Superior Infection Free Graft Survival. Results from a Steroid Sparing Transplant Group

H. Sharma, A. Odugoudar, B. Devkaran, A. Rao, A. El-Bakry, T. Gunawardhane, D. Ridgway, M. Howse, S. Mehra

7:00pm-8:00pm

Standard Induction with Basiliximab versus no Induction in Low Immunological Risk Kidney Transplant Recipients: Study Protocol for a Randomized Controlled Trial

A. Ajlan¹, H. Aleid¹, T. Ali¹, H. Joharji¹, Z. Alabdulkarim¹, T. Aburiash¹, K. Almeshari¹, A. Nazmi¹, Y. Shah¹, E. Devol¹, D. Alkortas¹, D. Broering¹, I. Alahmadi¹, A. Ullah¹, A. Alotaibi¹, A. Aljedai²

7:00pm-8:00pm

Suppressive Effect of De Novo Everolimus on Primary Cytomegalovirus Infection in Kidney Transplant Recipient

S. Harada¹, H. Sasaki², Y. Takada², D. Takamoto², H. Harada², T. Hirano², H. Tanaka¹